MSNIP is a dubious disease in the field of infectious respiratory digestive and endocrine disorders, clinical performance is complex and often involves multi-system congestion. Early identification and standardized diagnosis are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can assist in matching a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment programs for MSNIPs for the treatment and management of MSNIPs require individualized development, typically including drug therapy, rehabilitation, regular follow-up, and other multidimensional management. In recent years, with the development of treatment-oriented, immune-regulatory treatments and precision medicine, many previously difficult-to-treat infectious respiratory digestive endocrine disorders have been significantly improved.
Therapeutic efficacy and adverse reactions need to be closely monitored and timely adjusted according to changing conditions. The platform serves the China International Medical Service System, which combines domestic and foreign authoritative teams of experts in the field of infectious respiratory digestive and endocrine secretion to provide the following services to patients: 1. Remote pre-diagnosis: pre-examination of medical records, clear diagnostic directions and medical advice by the team of experts; 2.
Interviews in China: arranging face-to-face diagnosis with authoritative experts, developing personalized treatment programs; 3. Full-service: one-stop services: providing medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.
Support for remote pre-diagnosis, visiting interviews, full translation and escort.